Objective: To investigate the efficacy of intermittent doxazosin therapy on LUTS associated BPH. Material & Method: This study was performed between January to April 2010 enrolling 20 patients with LUTS associated BPH. Study subjects were randomly allocated to 2 therapeutic groups. The first group was assigned daily doxazosin therapy (11 patients), while the second group was assigned intermittent doxazosin therapy (9 patients). Initially all subjects were given doxazosin 2 mg daily for 2 weeks. Subsequently group I received doxazosin 2 mg daily therapy, while group II received doxazosin 2 mg every other day. All medications were taken up to 12 weeks. Outcomes were evaluated prior to therapy, and after 2, 4, 8, and 12 weeks of therapy. Efficacy of doxazosin therapy was measured by International Prostate Symptom Score (IPSS), peak urinary flow rate (Q max), and residual urine volume. Statistical analysis was performed to evaluate difference in efficacy between the treatment groups. Results: Daily doxazosin therapy for 2 weeks resulted in significant improvement of Q max and IPSS. After 4, 8, and 12 weeks significant improvement was maintained in both daily and intermittent groups, as measured by Q max, residual urine volume and IPSS. There were no significant differences in Q max, residual urine volume, and IPSS between the daily and intermittent groups at 4, 8, and 12 groups. Conclusion: There were significant improvements of Q max, residual urine and IPSS at 2 to 12 weeks in daily as well as intermittent doxazosin therapy groups. There were no significant differences in efficacy between daily and intermittent therapy groups
Leveillee RJ. Prostate Hyperplasia, Benign. Viewed
September 27, 2008.
M cC o n n ell J D . C o mb in atio n th er ap y s ig n i- ficantly delays progression of benign prostatic hyperplasia. Viewed September 27, 2008.
Roehrborn CG, McConell JD. Etiology, patophy- siology, and natural history of benign prostatic hyperplasi. In: Walsh PC, Retik AB, et al. Eds: Campbell's Urology. 9th ed. Philadelphia: WB. Sauders; 2007. p. 1297-330.
Stanley J, Swierzewski. Benign prostatic hyperplasia
(BPH)/enlarged prostate. Viewed March 6, 2008.
Protocols. Benign prostatic hyperplasia (BPH). Online references for health concerns. Viewed January 10,
Greenstein MA. Enlarged prostate. Medical Encyclo- p e d i a . Vi e w e d J a n u a r y 1 0 , 2 0 0 9 . < w w w. emedicinehealth.com/enlargedprostate/ article>
Kirby R, Lepor H. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Walsh
PC, et al. Campbell's Urology. 9th ed. 2007. Chapter 87.
Langworth L. Prostate gland enlargement. Viewed 10
Yokoyama T, Watanabe T, Saika T, Nasu Y, Kumon H, Miyaji Y, et al. Natural course of lower urinary tract symptoms following discontinuation of alpha-1- adrenergic blockers in patients with benign prostatic hyperplasia. Int J Urol 2009; 14: 598-601. Viewed September 12, 2009.
Charnow JA. Intermittent therapy may be an option for LUTS. Viewed March 20, 2009.
Jeong HJ, Lee DH. The efficacy of every other day alpha-blocker therapy in men with benign prostatic hyperplasia. Korean J Urol 2005; 46 (4): 366-9.Viewed September 12, 2009
Kaplan SA. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms. J Urol 1998; 52 (1).
Yanardag H, Goktas S, Kibar Y, Kilic S, Erduran D. Intermittent tamsulosin therapy in men with lower urinary tract symptoms. J Urol 2005; 1 7 3 : 1 5 5 - 7 . Vi e w e d S e p t e m b e r 1 2 , 2 0 0 9 .
Roehrborn CG, McConnell JD. The management of benign prostatic hyperplasia. Viewed September 12,
McConnell JD, Abrahams P. Evaluation and treatment of LUTS in older men. In: The male urinary tract d y s f u n c t i o n e v a l u a t i o n a n d m a n a g e m e n t . Disampaikan pada 6th International Consultation on New Development in Prostate Cancer and Prostate Disease; 2005.
Jones DA. Benign prostatic hypertrophy and lower urinary tract dysfunction. In: Comprehensive Urology
Rosette JL, Alivizatos G. Guidelines on benign prostatic hyperplasia. In: Guidelines of European Association of Urology; 2008.
Roerig. Cardura (doxazosin mesylate) drug information: Uses, side effects, drug interactions, warnings. Viewed October 20, 2009
Fawzy A. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Urology 1999; 53: 329-35.
Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patient with mild to moderate essential hypertension, a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-5